Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II

J Am Coll Cardiol. 2003 Feb 19;41(4):666-73. doi: 10.1016/s0735-1097(02)02860-7.

Abstract

Objectives: We investigated if endothelin (ET)-1 and the renin-angiotensin-aldosterone system play a role in cardiac fibrosis.

Background: Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood.

Methods: Four-week-old transgenic (mRen2)27 rat (TGRen2) received for four weeks a placebo, the mixed ET(A)/ET(B) endothelin receptor antagonist bosentan, the angiotensin II type I receptor (AT-1) antagonist irbesartan, the ET(A) endothelin receptor antagonist BMS-182874, and a combined treatment with irbesartan plus BMS-182874. We measured collagen density on Sirius red-stained serial sections of the left ventricle (LV) with a photomicroscope equipped with specific software and assessed the gene expression of procollagen alpha1(I), atrial natriuretic peptide (ANP), transforming growth factor-beta 1 (TGFbeta1), endothelin converting enzyme, and ET(B) receptor.

Results: In the placebo group, hypertension was associated with LV hypertrophy and cardiac fibrosis (LV weight: 4.0 +/- 0.3 mg/g body weight; collagen density: 2.21 +/- 0.16%), which were all prevented with irbesartan (2.3 +/- 0.1, 1.30 +/- 0.13, p < 0.001), but not with BMS-182874 (4.0 +/- 0.2, 2.41 +/- 0.22). Bosentan also prevented fibrosis (1.39 +/- 0.18) but not hypertension and LV hypertrophy (3.38 +/- 0.27). Combined irbesartan and BMS-182874 treatment prevented LV hypertrophy (2.9 +/- 0.1) but not fibrosis (2.52 +/- 0.16). Collagen density correlated (r = 0.414, p < 0.05) with plasma aldosterone levels. In TGRen2 with LV hypertrophy, the gene expression of ANP and ET(B) but not that of TGFbeta1 and procollagen alpha1(I) was increased.

Conclusions: In Ang II-dependent hypertension, cardiac fibrosis was associated with LV hypertrophy and was hindered by both mixed ET(A)/ET(B) blockade and AT-1 blockade. Only the latter treatment prevented both hypertension and LV hypertrophy. Thus, there is a dissociation between the mechanisms of cardiac fibrosis and hypertension, which do and do not entail ET-1, respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / adverse effects*
  • Animals
  • Animals, Genetically Modified
  • Antihypertensive Agents / pharmacology
  • Biphenyl Compounds / pharmacology
  • Bosentan
  • Cardiomyopathies / etiology*
  • Cardiomyopathies / pathology
  • Cardiomyopathies / physiopathology*
  • Dansyl Compounds / pharmacology
  • Disease Models, Animal
  • Endothelin-1 / drug effects
  • Endothelin-1 / physiology*
  • Fibrosis / etiology*
  • Fibrosis / pathology
  • Fibrosis / physiopathology*
  • Hypertension / chemically induced*
  • Hypertension / complications
  • Hypertension / physiopathology*
  • Irbesartan
  • Male
  • Rats
  • Receptor, Angiotensin, Type 1
  • Receptors, Angiotensin / drug effects
  • Receptors, Angiotensin / physiology*
  • Receptors, Cell Surface / drug effects
  • Receptors, Cell Surface / physiology
  • Sulfonamides / pharmacology
  • Tetrazoles / pharmacology
  • Time Factors
  • Vasoconstrictor Agents / adverse effects*

Substances

  • Antihypertensive Agents
  • Biphenyl Compounds
  • Dansyl Compounds
  • Endothelin-1
  • Receptor, Angiotensin, Type 1
  • Receptors, Angiotensin
  • Receptors, Cell Surface
  • Sulfonamides
  • Tetrazoles
  • Vasoconstrictor Agents
  • Angiotensin II
  • 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide
  • Irbesartan
  • Bosentan